Page 2 - Biotech

Accelerating growth: Progress in India's biotech sector looks promising

According to the report, titled "India Bioeconomy Report 2025", the bioeconomy sector witnessed a 16-fold expansion in the past decade, from $10 billion in 2014 to $165.7 billion in 2024

Aquaconnect commits $4.5 million for aquaculture biologicals R&D

This initiative reinforces the company's mission to provide deep life sciences-backed, innovative shrimp and fish health and farm care solutions

Genome India Project: A milestone towards precision medicine and treatment

The Genome India Data, which captures the genetic diversity of India's population, will be available to researchers at the Indian Biological Data Centre (IBDC) through managed access

Medtech sector seeks standard GST rate, export incentives in Budget

The scheme aims to refund to exporters the embedded central, state, and local duties and taxes paid on inputs that were so far not refunded or rebated

Biocon Biologics marks one year as global biosimilars enterprise

It is targeting a $100 m inventory improvement by March

Big Pharma's bet on China biotech a rare trade bright spot amid tensions

Chinese biomedical research is on the cusp of a breakthrough just as the industry starts to face serious headwinds

India's bioeconomy at $150 billion, innovation crucial for growth: BIRAC MD

India's biotechnology sector is witnessing remarkable growth, with the country's bioeconomy now valued at USD 150 billion but there is still significant untapped potential in innovation and product development, which could further elevate India's global standing in the sector, Dr Jitendra Kumar, Managing Director of the government's Biotechnology Industry Research Assistance Council (BIRAC), said. BIRAC is a not-for-profit public sector enterprise set up by the Department of Biotechnology (DBT) under the government that supports and promotes innovation, entrepreneurship, and research in the sector. In an interview with PTI, Kumar highlighted India's significant contributions to global healthcare, with 40 per cent of the world's generic medicines being supplied by Indian companies. "We have enormous potential and capability, but when it comes to the value of our bioeconomy, we are ranked 14th globally. This is because much of the value stems from patented, innovative products' -- an

Agri biotech firm BioPrime raises $6mn in Series A funding led by Edaphon

Startup founded in 2016 say it will use the investment for crop protection research, products

Investors betting on India, Korea to fill gaps from US Biosecure Act

The Biosecure Act would restrict federally funded medical providers from contracting with a select group of Chinese biotech companies

US bill to restrict business with China's biotech companies passes House

The US Senate's Homeland Security committee voted in March to approve a similar bill

Concord Biotech shares hit all time high; Antique Broking reiterates 'Buy'

Antique Broking is bullish on Concord's business model, new launches and niche products

Merck Life Science partners with Aragen to boost biotech R&D in India

Merck Life Science will supply equipment and technologies to Aragen, facilitating a more efficient clinical-to-commercial process timeline

Lord's Mark Microbiotech set to launch saliva-based organ age test

The company claims this test will be priced between Rs 15,000 and 20,000, making it more affordable than the current market options, which range from Rs 30,000 to 40,000

Karnataka to triple its BioEconomy to $100 billion by 2030: Govt report

The report reveals that the number of startups in the state has surpassed 1,000, with a notable increase in biotech ventures

Syngene Q4 results: Net profit up 6% to Rs 189 cr, revenue declines 8%

Syngene International shares ended the day's trade on BSE at Rs 694.2 apiece, down one per cent

Biocon signs deal with Biomm SA to commercialise diabetes drug in Brazil

Biomm SA develops and commercialises complex biotech and biosimilar drug products

Bharat Biotech, Bilthoven Biologicals collaborate for oral polio vaccines

Bharat Biotech on Tuesday said it has collaborated with the Netherlands-based Bilthoven Biologicals B.V, a wholly-owned arm of Serum Institute of India, to strengthen production and supply security of oral polio vaccines. An agreement has been signed between the two partners under which Bharat Biotech will procure drug substances for the production of oral polio vaccines (OPVs) to be supplied within India and globally, the company said in a statement. Through this collaboration, Bharat Biotech and Bilthoven Biologicals (BBio) will jointly obtain regulatory approvals and licences required to commercially manufacture OPVs in India for global supplies from drug substances manufactured in the Netherlands at BBio, it added. "This collaboration...exemplifies cooperation between vaccine companies, ensuring a secure supply of oral polio vaccines and fortifies the nation's mission to eradicate polio," Bharat Biotech Executive Chairman Krishna Ella said. Serum Institute of India CEO Adar ...

Healthcare innovation to double at $60 bn opportunity by FY28 in India

Indian vaccines and biotech market, which was valued at $4 billion in FY23, accounting for 15 percent of the innovation market, has quickly grown from $1.2 billion in FY20

US rivalry with China expands to biotech, lawmakers see failure to compete

US lawmakers are raising alarms about what they see as America's failure to compete with China in biotechnology, warning of the risks to US national security and commercial interests. But as the two countries' rivalry expands into the biotech industry, some say that shutting out Chinese companies would only hurt the US. Biotechnology promises to revolutionise everyday life, with scientists and researchers using it to make rapid advances in medical treatment, genetic engineering in agriculture and novel biomaterials. Because of its potential, it has caught the attention of both the Chinese and US governments. Bills have been introduced in the House and Senate to bar foreign adversary biotech companies of concern from doing business with federally funded medical providers. The bills name four Chinese-owned companies. The Chinese Embassy said those behind the bills have an ideological bias and seek to suppress Chinese companies under false pretexts. It demanded that Chinese companies b

Falling biotech funding may be a bitter pill to swallow for CDMOs

Indian CDMOs are focusing on big biotech clients, and going forward, they believe the funding issues will not last long